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AbstrAct
Aim To evaluate the relationship between macular 
pigment optical density (MPOD) and glare disability in 
open-angle glaucoma.
Methods A cross-sectional analysis of baseline data (88 
subjects; median age, 67 (range 36–84) years) collected 
during the Macular Pigment and Glaucoma Trial (ISRCTN 
registry number: 56985060). MPOD at 0.25°, 0.5° and 
1° of retinal eccentricity was measured using customised 
heterochromatic flicker photometry. Mesopic contrast 
sensitivity with glare (mCSg), photostress recovery time 
(PRT) and self-reported glare symptoms were evaluated. 
Fourier-domain optical coherence tomography was used 
to analyse ganglion cell complex (GCC) and identify 
foveal involvement.
results Low spatial frequency (f) mCSg was 
significantly correlated with MPOD at 0.25° (three cycles 
per degree (cpd): r=0.25, p=0.04) and 0.5° (three cpd: 
r=0.23, p=0.04) of retinal eccentricity. Those with foveal 
GCC loss exhibited lower MPOD, had worse low spatial 
fmCSg (1.5 cpd and 3 cpd, p=0.02 each) and prolonged 
PRT (p=0.02) in comparison with those without foveal 
involvement. The depth of central 10° field loss was 
related to MPOD at all eccentricities (p<0.01 for all). 
Those who reported glare symptoms had a significantly 
lower MPOD at all retinal eccentricities (0.25° and 1°: 
p=0.05 each; 0.5°: p=0.04), including those with foveal 
involvement (0.25°: p=0.05; 0.5°: p<0.01; 1°: p=0.01).
conclusions Macular pigment level may be an 
important consideration among those experiencing 
disability glare in glaucoma, including those with foveal 
involvement.
IntroductIon
Disability glare impairs vision when light scatters 
within the eye and casts a veiling luminance on 
the retina. This causes a loss of image contrast and 
decreases the visibility of objects near the source of 
glare.1 Individuals with glaucoma commonly suffer 
from disability glare, and this has been shown to be 
present even in those with mild visual loss.2 3 The 
aetiology of glare disability in glaucoma is poorly 
understood and, currently, little can be offered to 
the patient to alleviate this debilitating problem. 
Recent evidence pertaining to the involvement of 
the macula in glaucoma,4 however, has provided a 
rationale for the exploration of macular pigment 
(MP) in relation to functional (including glare 
related) visual loss associated with glaucoma.
MP is composed of the hydroxycarotenoids lutein, 
zeaxanthin and meso-zeaxanthin and is found to be 
highly concentrated at the central macula.5 Apart 
from its antioxidant properties and role as a filter 
for short wavelength blue light, it is also believed 
to play a beneficial role in visual performance.6–13 It 
has been shown that healthy individuals with higher 
macular pigment optical density (MPOD) expe-
rience less disability glare and demonstrate better 
photostress recovery times (PRT).7 8 10 Further-
more, oral dietary MP supplementation has been 
shown to increase MPOD and thereby improve 
glare disability and PRT in healthy individuals.9 12 
Similar to glaucoma, individuals with age-related 
macular degeneration (AMD) commonly suffer 
from disability glare even in the presence of early 
disease.14 Dietary MP supplementation has also 
been shown to increase MPOD and thereby elicit 
an improvement in visual function including visual 
acuity (VA), contrast sensitivity (CS) and subjective 
glare recovery in AMD subjects.13
It has recently been demonstrated that MPOD is 
lower in glaucomatous eyes relative to age-matched 
normal eyes.15 16 Additionally, MPOD appears 
to be lowest among those glaucoma subjects with 
more severe structural damage and, in particular, 
in the presence of retinal ganglion cell complex loss 
involving the foveal region.17 Based on the evidence 
that lower MPOD may be associated with disability 
glare, this study was designed to evaluate whether 
MP may relate to functional performance in the 
glaucomatous eye.
Methods
subjects
This paper analyses the baseline glaucoma-re-
lated functional data that were collected from the 
Macular Pigment and Glaucoma Trial (ISRCTN 
registry number: 56985060). Information on this 
placebo-controlled, double-masked randomised 
trial is available online at http://www. isrctn. com. 
A total of 88 subjects with a diagnosis of open-
angle glaucoma were recruited. Written informed 
consent was obtained from all subjects, and the 
study adhered to the tenets of the Declaration of 
Helsinki.
All subjects with a diagnosis of open-angle glau-
coma displayed glaucomatous optic disc cupping 
with compatible visual field (VF) loss and an open 
anterior chamber angle on gonioscopy. Four different 
types of open-angle glaucoma were considered for 
this trial: (1) primary open-angle glaucoma, where 
there is no associated ocular or systemic disease, 
(2) normal-tension glaucoma, where intraocular 
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pressure is within the normal range, (3) pseudoexfoliative glau-
coma, which is characterised by fibrillar protein deposition in 
the ocular anterior segment and (4) pigmentary glaucoma, which 
is characterised by excessive pigment deposition in the ocular 
anterior chamber angle.
The inclusion criteria were age >18 years, ETDRS LogMAR 
VA of 0.30 or better and subject ability to adhere to the trial 
protocol. Exclusion criteria comprised of any ocular disease such 
as AMD or moderate-to-significant cataract (Lens Opacity Clas-
sification System III (LOCS III) grades C3-5, P3-5, NC3-5 or 
NO3-5), previous ocular surgery other than cataract extraction 
or glaucoma drainage procedure, presence of a blue-filter intra-
ocular lens, underlying diagnosis of diabetes mellitus, consump-
tion of an oral dietary MP supplement in the past 6 months 
and the use of a miotic agent. The LOCS III18 grades cataracts 
by type (cortical: C1-5 and posterior subcapsular: P1-5) and 
nuclear appearance (nuclear colour: NC1-6 and nuclear opal-
escence: NO1-6). We used the LOCS III standards were used to 
categorise eyes according to lens appearance as either ‘mild cata-
ract’ (grades C1-2, P1-2, NC1-2 and/or NO1-2) or ‘no cataract’ 
(C0, P0, NC0 and/or NO0).
Details relating to age, gender, type of glaucoma, years diag-
nosed with glaucoma, history of smoking (current smoker, 
ex-smoker and never smoked), body mass index (kg/m2) and lens 
status (phakic vs pseudophakic) were recorded for each subject. 
All subjects also underwent a comprehensive slit lamp biomi-
croscopy examination. If both eyes met the inclusion criteria, 
the study eye was determined by random assignment using the 
software programme Research Randomizer (V.4.0).19
Measurement of the MP spatial profile
Heterochromatic flicker photometry (HFP) is a psychophys-
ical technique for measuring MPOD that has been validated 
against the absorption spectrum of in vitro preparations of 
liposome-bound MP20 and shown to produce good test–retest 
reliability when compared with other methods of measuring 
MPOD.21 The HFP procedure is also minimally invasive, and 
pupil dilatation is not necessary. Furthermore, it has been shown 
that variation in pupil size has no effect on the final measure-
ment and that the presence of cataract does not significantly 
affect the measurement.22 23 A customised HFP (cHFP) approach 
whereby the flicker frequency was optimised to take account 
of individual differences in vision as influenced by age, ocular 
disease or other factors was employed to optimise the task and 
thereby minimise the likely variance between readings.24 MPOD 
was measured at 0.25°, 0.5° and 1° under conditions of dimmed 
light with a Macular Densitometer (Macular Metrics, Reho-
both, Massachusetts, USA) using the cHFP approach. Measure-
ments taken at 7° of eccentricity were used as a reference point 
where MPOD was assumed to be nil. Subjects were instructed 
to view a stimulus consisting of a square wave alternating blue 
(460 nm) and green (550 nm) flickering LED light source and 
were required to ascertain the point at which the flicker stopped 
or was minimally detectable (isoluminance match). For each test 
point, five readings were obtained to produce a mean MPOD at 
each eccentricity. Measurements were considered unreliable and 
excluded from data analysis if there was a large variance between 
measures (SD >0.05) for each test point.
dietary intake of lutein and zeaxanthin
All glaucoma subjects completed the Lutein Zeaxanthin Ques-
tionnaire (Carotenoid & Health Laboratory, Jean Mayer USDA 
Human Nutrition Center on Aging, Tufts University, Medford, 
Massachusetts, USA), which has been used in other MP 
studies.17 25 This semiquantitative food frequency questionnaire 
was used to quantify the dietary intake of lutein and zeaxanthin 
among glaucoma subjects in order to control for any disparity in 
MPOD between subgroups that may be caused by their respec-
tive diet.
cs with glare
The Optec 6500 device (Stereo Optical, Chicago, Illinois, USA) 
was used to objectively measure mesopic (3.0 cd/m²) CS under 
glare conditions (mesopic contrast sensitivity with glare (mCSg)) 
in all subjects. All testing was carried out on natural size pupils 
under a constant ambient light. The Optec 6500 is based on 
the Functional Acuity Contrast Test, which consists of a series 
of sine-wave grating charts and is designed to test sensitivity 
across five spatial frequencies (f) (1.5, 3, 6, 12 and 18 cycles per 
degree (cpd)) and nine levels of contrast in 0.15 log CS decre-
ments. The in-built glare source consists of 12 white LEDs that 
are arranged circumferentially to the grating charts. The glare 
source was preset to provide a medium intensity luminance of 
42 lux.11 26 With distance glasses, if necessary, each subject was 
required to identify the orientation of the grating (right, up or 
left) without guessing, starting from the lowest spatial f and the 
highest contrast. The last correct response for each spatial f was 
plotted on a CS curve. When the subject was not able to see 
the highest contrast setting at any spatial f, the result was docu-
mented as half the lowest CS value for that spatial f.
Photostress recovery
PRT was measured using the portable, handheld MDD-2 
Macular Adaptometer (Health Research Sciences, Lighthouse 
Point, Florida, USA) device, which has previously been used in 
other studies.27 28 It consists of a xenon flash source capable of 
producing a 200 μs duration flash that is subsequently filtered to 
block infrared and ultraviolet light before reaching the viewing 
eye. Each subject was instructed to hold the device up close to 
the study eye and to look through the 12 mm diameter viewing 
aperture, which contained an +8 dioptre-focusing lens. At the 
viewing aperture, the xenon flash reaches a peak irradiance of 
4.5 W/cm2, and the stimulus is of 0.41-radian angular subtense. 
At the start of the test, it was ascertained that each subject was 
able to recognise a LED display number. The test was abandoned 
if it was not identifiable to the subject. Afterwards, a push-
button was pressed to produce the xenon flash. The subject was 
required to call out a new numerical stimulus (single digit) that 
appeared simultaneous to the flash. This prompted the examiner 
to press a button to end the test. The time taken for the subject 
to correctly identify the stimulus was recorded as the PRT. If 
the response was incorrect, the test was repeated approximately 
20 min later. An upper PRT limit of 60 s was incorporated into 
the device, which automatically resets for a new test thereafter. 
In the event that the subject did not respond within 60 s, the test 
was abandoned.
Glare symptoms
In the evaluation of subjective glare symptoms, the subjects 
were asked the following question: ‘Do you suffer from glare?’. 
Examples of different scenarios (glare from a poorly shielded 
street lamp in a dark street; glare from an oncoming car head-
light while driving at night; and glare from low-lying sun in 
the winter) were used to provide context and assist them in 
answering this question better.
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VF assessment
The Swedish Interactive Threshold Algorithm Standard 24-2 
and 10–2 programmes available in the Humphrey Visual Field 
Analyser (HVFA II, Carl Zeiss Meditec, Jena, Germany) were 
used to assess differential light sensitivity as a measure of global 
glaucomatous VF loss and residual visual function in the central 
retina (within 10° of fixation), respectively. Mean deviation 
(MD) was used to define the severity of glaucoma (extent of 
functional loss) and was included in data analysis. Unreliable VF 
plots, as determined by a fixation loss of >33% and/or false posi-
tive/negative rates >20%, were excluded from analysis.
MP is most concentrated within the central 1° of the fovea. 
Although the 24-2 test pattern is useful in providing a global 
scale of glaucomatous VF loss, it uses a 6° x 6° grid, which 
only has four points within the central 4.2° radius of fixation. 
In contrast, the 10–2 test pattern uses a 1° x 1° grid, with the 
central four points corresponding to within 1.4° of the foveal 
centre. The finding of a glaucomatous depression involving any 
of the central four points of the 10–2 pattern deviation plots was 
recorded (foveal visual loss). For the study of MP and central 
visual function, we will focus on the MD of the 10–2 test for the 
purpose of statistical analysis.
Fourier-domain optical coherence tomography (Fd-oct)
The ganglion cell complex (GCC) protocol from the RTVue 
FD-OCT system (software V.5.1; Optovue, Fremont, California, 
USA) was used to categorise subjects’ glaucoma by foveal involve-
ment. This method had been described in detail previously.17 In 
the GCC significance map, GCC thickness is colour coded by the 
significance of GCC thickness reduction (red, p<1%; yellow, 
p<5%; green, p≥5%). It was classified as ‘fovea-not-involved’ 
(ie, no GCC loss encroaching the fovea) if the perimeter of the 
fovea zone was green in colour, and as ‘fovea-involved’ (ie, GCC 
loss encroaching the fovea) if the red scale encroached up to the 
perimeter of the fovea zone. The GCC subgroups allowed us to 
compare visual function by foveal involvement, which was previ-
ously shown to be associated with significantly lower MPOD.
statistical analysis
The SPSS statistical software package (V.22.0; IBM, New York, 
USA) was used for data analysis. All variables were tested for 
normality using either Kolmogorov-Smirnov test (if n>50) 
or Shapiro-Wilk test (if n≤50). All data are presented as 
mean±SD for normally distributed data and as median (range) 
for non-normal distributions. Parametric tests (Pearson correla-
tion coefficient and independent t-test) or non-parametric tests 
(Spearman Rho test and Mann-Whitney U-test) were carried out 
where appropriate. As the presence of a cataract can influence 
mCSg results, we controlled for this factor in our analysis. Linear 
regression analysis was also performed; R2 value signifies the 
percentage of variability in the dependent variable that can be 
explained by the model with the independent variable (MPOD). 
When comparing categoric data, a χ2 test was used. A 5% statis-
tical significance level of was adopted throughout the analysis.
results
Successful MPOD measurement was obtained for 69 subjects 
(78.4%) at 0.25° retinal eccentricity, 81 subjects (92%) at 0.5° 
eccentricity and 59 subjects (67%) at 1° of eccentricity. No 
significant relationship was observed between MPOD and 
potential confounders for any relationship that might exist 
between MPOD, visual function and other demographic param-
eters, including gender, time diagnosed with glaucoma, type of 
glaucoma, body mass index, lens status (mild cataract: yes or 
no) or smoking status (p>0.05), except for age, which demon-
strated a statistically significant relationship with MPOD at 0.5° 
of retinal eccentricity only (r=−0.23, p=0.04). Subsequent 
analyses involving MPOD at 0.5° of retinal eccentricity were 
corrected for age.
Glare and photostress recovery
With controlling for the presence of mild cataract, MPOD was 
found to be statistically significantly correlated with mCSg for 
low spatial fs only, at both 0.25° (3 cpd: r=0.25, p=0.04) and 
0.5° (3 cpd: r=0.23, p=0.04) of retinal eccentricity. No signif-
icant correlation was found between MPOD at 1° and mCSg. 
Linear regression analyses showed a low R2 value between 
MPOD and mCSg for low spatial fs (range 3%–7%). Mann-
Whitney U-test was performed to evaluate any possible effect of 
cataract on glare, and no significant differences in mCSg were 
found at any f between those with and those without mild cata-
ract (p values range 0.75–1.0).
In response to the glare symptoms question, 61% (n=54) 
of subjects stated that they suffer from glare symptoms, with 
a median duration of 4.5 years (range 0.5–30). Those who 
suffered from glare symptoms had a significantly lower MPOD 
at all eccentricities relative to those without glare symptoms 
(figure 1), but no difference in terms of age, gender, length of 
glaucoma diagnosis, body mass index, lens status or dietary 
intake of lutein and zeaxanthin (table 1).
Valid PRT data were available for 73 subjects with a median of 
19 s (range 8–59). The remaining subjects were either unable to 
see the display number in the Macular Adaptometer (n=4) or to 
respond within the 60 s limit following the xenon flash (n=11). 
There was no correlation between MPOD and PRT (p>0.05 for 
all).
VF loss
HVF 24-2 MD was significantly correlated with MPOD (r=0.33, 
p<0.01 at 0.25°; r=0.33, p<0.01 at 0.5°; r=0.31, p=0.02 at 
1°). The median MD for HVF 10–2 was −7.85 dB with a range 
of −0.28 to −30.9. Using the 10–2 pattern deviation plots, we 
found 51.5% (n=45) of subjects without foveal visual loss in 
contrast to 48.9% (n=43) with foveal visual loss. However, 
Figure 1 Graph demonstrates lower MPOD levels in those with 
symptoms of glare compared with those who were symptom free. 
MPOD, macular pigment optical density.
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none of the latter displayed the findings of depression of all four 
central points on the 10–2 pattern deviation plots suggesting the 
possibility of reliable subject fixation of the Macular Densitom-
eter stimulus targets to within 1.4° of the foveal centre. MPOD 
at all retinal eccentricities were positively and statistically signifi-
cantly correlated to the total amount of central visual field loss 
as measured using the HVF 10–2 MD (r=0.33, p<0.01 at 0.25°; 
r=0.33, p<0.01 at 0.5°; r=0.32, p=0.01 at 1°) (figure 2). 
Linear regression analyses between MPOD (0.25°, 0.5° and 1° of 
retinal eccentricity, respectively) and HVF 10–2 MD showed a 
R2 ranging from 10% to 12%.
Gcc subgroups
No confounding differences were found between the GCC 
subgroups for gender, body mass index, length of time diag-
nosed with glaucoma, dietary intake or smoking habits except 
age (‘fovea-not-involved’ vs ‘fovea-involved’, 62.6±10.4 years 
vs 67.9±9.0, p=0.02), which was accounted for in subsequent 
analyses. A general linear analysis confirmed that age did not 
have a significant effect on parameters such as low spatial f 
mCSg, PRT, HVF 10–2 MD and self-reported glare symptoms 
(p>0.05 for all).
Low spatial f mCSg was significantly worse in the ‘fovea-in-
volved’ subgroup compared with those without foveal involve-
ment (1.5 cpd: Z=−2.26, p=0.02; 3 cpd: Z=−2.36, p=0.02) 
(table 2). Additionally, the ‘fovea-involved’ subgroup had a 
prolonged PRT in comparison with the ‘fovea-not-involved’ 
subgroup (Z=−2.41, p=0.02). In the ‘fovea-involved’ subgroup, 
low spatial f mCSg was positively and statistically significantly 
correlated with MPOD at 0.25° (1.5 cpd: r=0.37, p=0.02; 3 
cpd: r=0.43, p=0.01) and 0.5° (1.5 cpd: r=0.29, p=0.05; 3 
cpd: r=0.41, p=0.01) of retinal eccentricity, while no signif-
icant correlation was observed at 1° and higher mCSg spatial 
fs. Of those with significant correlations, R2 was found to be 
between 8% and 20%. No significant correlation was observed 
between MPOD and mCSg in the ‘fovea-not-involved’ subgroup 
(p>0.05 for all). Furthermore, MPOD was significantly lower 
at all retinal eccentricities in those with foveal involvement who 
reported glare symptoms compared with those without glare 
symptoms (0.25°: p=0.05, t=−1.99; 0.5°: p<0.01, t=−2.92; 
1°: p=0.01, t=−2.63), while no significant difference was 
observed in the ‘fovea-not-involved’ subgroup (p>0.05 for all). 
No significant correlation was observed between MPOD and 
PRT within either GCC subgroup (p>0.05). Residual visual 
function, as determined by HVF 10–2 MD, was significantly 
worse (Z=−4.42, p<0.001) in the ‘fovea-involved’ subgroup 
(median, −12.17 dB (range −0.28 to −26.78)) in comparison 
with the ‘fovea-not-involved’ subgroup (median, −4.42 (range 
−1.02 to −20.62)).
dIscussIon
This study demonstrates for the first time that a relationship 
exists between MPOD and disability glare in the glaucomatous 
eye. Low MP levels appear to be associated with poorer mCSg 
at low spatial f and with increased symptoms of disability glare. 
More interestingly, it appears that this relationship between 
MPOD, mCSg and glare symptoms in individuals with glaucoma 
is mediated by foveal involvement.
Glare-affected visual performance under mesopic condi-
tions linearly correlates with the optical density of MP among 
glaucoma subjects, particularly at lower spatial f. Our finding 
that higher MP is associated with improved glare-related visual 
performance is consistent with other reports,7 9 10 although some 
studies have failed to replicate such findings for mesopic CS.12 28 
The inconsistency in the results among studies may be explained 
by the variation in population demographics, disease status and 
study methodology. Mesopic conditions were prioritised herein 
due to previous observations that impaired dark adaptation and 
disability glare can be found in glaucoma,2 29 30 coupled with 
evidence that glare-affected CS in the home environment is 
compromised due to poorer lighting.31 Although the study of 
MP in the glaucomatous eye is novel, other studies of MP in 
the non-glaucomatous eye have indicated that higher MPOD 
table 1 Self-reported glare symptoms and their characteristics
no glare Glare p
MPOD
  0.25°, mean±SD 0.27±0.15 0.20±0.13 0.05*
  0.5°, mean±SD 0.22±0.13 0.16±0.12 0.04*
  1°, median (range) 0.15 (0–0.28) 0.09 (0–0.25) 0.05†
Age, mean±SD 64.5±9.6 66±10.4 0.51*
Gender
  Male, n (%) 16 (47.1) 32 (59.3)
  Female, n (%) 18 (52.9) 22 (40.7) 0.28‡
Length of glaucoma diagnosis, 
median (range) (year)
6 (0.5–15) 6.5 (0.5–32) 0.60†
Body mass index, median (range) 
(kg/m2)
26.3 (18.7–39) 25.3 (18.5–42) 0.80†
Lens status
  Phakic, n (%) 30 (40) 45 (60)
  Pseudophakic, n (%) 4 (30.8) 9 (69.2) 0.56‡
Dietary intake, median (range) (mg/dL)
  Lutein 0.85 (0–13.2) 0.7 (0–5.2) 0.52†
  Zeaxanthin 0.1 (0–1.1) 0.1 (0–1.2) 0.15†
HVF 10–2 MD, median (range) (dB) −7.85 (−0.28 to 
−24.12)
−7.75 (−1.02 to 
−30.94)
0.44†
*Mann-Whitney U-test.
†Independent t-test.
‡χ2 test.
HVF, Humphrey visual field; MD, mean deviation; MPOD, macular pigment optical 
density; p, significance (two tailed). 
Figure 2 Scatter plots (A– C) show the correlation between MPOD and HVF 10–2 MD. HVF, Humphrey visual field; MD, mean deviation; MPOD, 
macular pigment optical density.
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and oral dietary MP supplementation can be beneficial towards 
improving CS including CS under the influence of glare.7–10 12
Depressed levels of CS in the glaucomatous eye can be 
explained, in part, by the disturbance at the macula.32 Our 
finding that mCSg at low spatial f significantly correlates with 
MPOD only in the ‘fovea-involved’ subgroup is not surprising 
as the fovea represents the most central anatomic location where 
MP density is highest. GCC thickness is linearly correlated with 
MPOD16 17; lower central MP in those with foveal-involved 
glaucoma may, therefore, be accountable, at least in part, for 
glare disability in these eyes. However, given the weak associa-
tion between MPOD and mCSg at low spatial fs, there are other 
factors, in particular, retinal changes (retinal ganglion cells and 
photoreceptors) in the glaucomatous eye that require consid-
eration. Studies have demonstrated an association between 
decreased CS in the glaucomatous eye and retinal ganglion cell 
dysfunction33 or death.34 In addition, MP is localised to the 
photoreceptor and retinal ganglion cell layers.5 Therefore, the 
loss of retinal ganglion cells33 34 and photoreceptors,35 as encoun-
tered in glaucoma, can contribute to lower MPOD. We would 
like to highlight that the retinal factors affecting CS and storage 
of MP cannot be excluded in our experiments. Our finding of 
a relationship between MPOD and mCSg in the glaucomatous 
eye is novel and interesting, and future studies are required to 
interpret this further.
Those who reported the experience of symptomatic glare 
exhibited lower MPOD levels. This provides additional evidence 
that glare disability is potentially linked to residual MP levels 
in glaucoma. Our overall findings suggest that lower levels of 
MPOD in the glaucomatous eye might represent a contrib-
utory factor to the effects of reduced mCSg and symptomatic 
glare disability. Furthermore, we observed that the relationships 
between MPOD and both mCSg and glare symptoms respec-
tively are isolated to those with foveal GCC loss. This suggests 
that further emphasis should be given to GCC analysis in glau-
coma as foveal involvement relates to lower MPOD and poorer 
residual visual function. There is substantial evidence to support 
the role of MP in improving visual performance in healthy 
eyes6–12 and in those with AMD.13 Oral dietary MP supplemen-
tation can augment MPOD and thereby effect an improvement 
in visual function such as disability glare, PRT and CS under 
glare conditions.9 12 13 Further research is needed to investigate 
the therapeutic potential of oral dietary MP supplementation 
for improving glare disability especially in those with foveal-in-
volved glaucoma.
There is strong evidence in the literature to suggest good 
structure–function relationship between macular RGC thinning 
and macular VF loss as measured by HVF 10–2.4 We included 
HVF 10–2 as an ancillary test to capture macular function for 
this purpose. Our finding that HVF 10–2 MD was significantly 
worse in the foveal GCC loss subgroup in comparison with those 
without foveal involvement reinforces previous findings where 
MPOD positively correlated with GCC thickness and where those 
with foveal involvement displayed worse MPOD.16 17 Although 
this study does not define the relationship between field loss, 
MPOD and glare-related visual performance, the correlation 
between central visual field loss and MPOD represents a novel 
finding in the field of glaucoma and worthy of further research.
The mechanisms underlying an abnormal PRT among individ-
uals with glaucoma remains unclear. Our findings indicate that a 
relationship between MPOD and photostress recovery is confined 
to those with foveal-involved glaucoma, who demonstrated a 
prolonged PRT. In a study comparing healthy controls and those 
with diabetes mellitus (with and without diabetic retinopathy 
subgroups), there was no difference in PRT between groups.28 
However, the study did not include those with diabetic maculop-
athy. There are conflicting results in the literature surrounding 
the relationship between MPOD and PRT. In a study of normal 
healthy controls, Stringham et al7 and Hammond et al10 each 
showed that MPOD correlated with photostress recovery in 
normal healthy controls while Loughman et al11 reported other-
wise. The variability of findings in the published literature may 
be explained by the differences in ocular pathology that were 
studied and the methods used to evaluate photostress recovery 
and MPOD, respectively.
There are limitations to this study. The HFP task can be chal-
lenging for some individuals, and this may affect the acquisition 
of MPOD measurements. We have applied stringent criteria and 
excluded readings that had large variances between them. This 
may have resulted in a high exclusion rate in the MPOD data 
that were available for statistical analysis. In the future, the use 
of fundus autofluorescence to measure MPOD will help elimi-
nate this problem.23 Another concern regarding the use of HFP 
in measuring MPOD in the glaucomatous eye is the ability of the 
subject to fixate and report the absence of flicker in the stim-
ulus targets. In this study, 48.9% of the subjects demonstrated 
some element of foveal visual field loss. This was determined by 
referring to the central four points (corresponding to 1.4° of the 
foveal centre) of the 10–2 pattern deviation plots. As no subjects 
had evidence of light sensitivity depression in all central points, 
and as all subjects demonstrated acceptable fixation stability 
throughout the test, inability to reliably maintain central fixation 
of the stimulus targets was not likely to be an issue. Despite this, 
we do acknowledge that we cannot exclude the possibility that 
patients’ glaucomatous foveal scotoma may have impacted their 
fixation capacity.
The lack of a healthy control group could be considered a 
drawback in this study. However, our main aim was to investigate 
table 2 Comparison of visual function between GCC subgroups
Fovea-not-involved subgroup Fovea-involved subgroup p
mCSg, median (range) (cpd)
  1.5 13 (3.5–50) 9 (3.5–36) 0.023
  3 20 (5–114) 10 (5–40) 0.018
  6 6 (6–85) 6 (6–45) 0.212
  12 4 (4–15) 4 (4–8) 0.127
  18 2 (2–4)     2 0.388
PRT, median (range) (s) 15 (8–59) 20 (9–58) 0.015
HVF 10–2 MD, median (range) (dB) −4.42 (−1.02 to −20.62) −12.17 (−0.28 to −26.78) <0.001
cpd, cycles per degree; GCC, ganglion cell complex; HVF, Humphrey visual field; mCSg, mesopic contrast sensitivity under glare condition; MD, mean deviation; PRT, 
photostress recovery time.
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the relationship between MPOD and glaucoma-related func-
tional parameters, in particular glare disability, rather than the 
comparison of visual function between glaucoma and controls. 
The latter has previously been widely studied in the literature, 
and it is known that functional measures such as CS with and 
without glare and PRT are affected in those with glaucoma, and 
therefore was not the primary focus in this study. The cross-sec-
tional nature of the study also limits the interpretation of the 
relationships that have been shown to exist but does serve to 
guide future research.
Those with ‘fovea-involved’ glaucoma were older in compar-
ison with those without foveal involvement, although the age 
difference was small and not clinically meaningful. Coexisting 
ocular pathologies such as cataract and macular changes are 
more common with increasing age and may affect visual func-
tions such as mCSg and PRT, respectively. We meticulously 
excluded individuals with moderate-to-significant cataract using 
the LOCS III grading, and therefore the possibility of a cataract 
as a confounding factor on mCSg was minimised. One possible 
limitation in this study is the absence of specific grading of the 
type and severity of mild cataract in this study. We showed, 
however, that cataract (those without cataract vs those with 
mild cataract) had no effect on mCSg in our study subjects. 
Furthermore, subsequent correlation analyses between MPOD 
and mCSg were also controlled for the presence of mild cata-
ract, so this potential limitation is relatively minor. Any indi-
viduals with coexisting AMD were not recruited into this study. 
We also excluded those with an underlying diagnosis of diabetes 
mellitus as the finding of concurrent diabetic retinopathy has 
been linked with reduced MPOD.25 Any possible residual age-re-
lated confounding effects were controlled for in our statistical 
analysis, thereby negating the potential issue.
Another limitation of this study is the inability to disen-
tangle the effects of disability and discomfort glare. Although 
the Optec 6500 device provides a consistent glare environment 
for our experiments, it is not discernible whether the measure-
ments recorded are solely disability glare alone. Discomfort glare 
may be a contributing factor to participant experience of glare. 
Our finding that those with self-reported glare symptoms have 
lower MPOD relative to those without symptoms is a potentially 
important finding. Interpretation of this finding, however, needs 
to be tempered in relation to the nature of the question posed 
to participants. The question was qualitative in nature and not 
associated with a Likert or other scale to categorise responses. 
Furthermore, the response was not probed to elucidate addi-
tional detail as to the nature of the symptoms where present. 
Despite this limitation, our findings appear robust and therefore 
warrant consideration for future work.
conclusIon
This study extends previous findings that MPOD is lower in 
glaucoma15 and associated with structural ganglion cell complex 
losses at the fovea.17 It demonstrates that lower MPOD levels 
among glaucoma subjects is associated with (A) more severe 
glaucomatous VF loss, (B) poorer CS for low spatial f stimuli 
under glare conditions and (C) self-reported symptoms of glare. 
More importantly, glaucoma-related psychophysical tests appear 
to be related to foveal GCC loss.
It is therefore possible to conclude that MP may have a role 
in the visual functional status of individuals with glaucoma, 
although a causal link has yet to be fully established. It is 
important to note that MP is only found in the central macula 
and therefore will not entirely explain the global symptom of 
disability glare but may be a contributing factor. The study of 
MP in glaucoma is of importance as the therapeutic potential 
to increase MPOD with an oral dietary MP supplement to 
improve disability glare is likely to appeal to patients with glau-
coma exhibiting such symptoms should it work. To explore this 
concept further, the Macular Pigment and Glaucoma Trial has 
been designed to evaluate the MPOD response to an oral dietary 
MP supplement and any effects on glare in glaucoma.
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